Art Mandell Departs from MaxCyte Board and Legacy Continues
Art Mandell's Departure from MaxCyte Board
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a pioneering company in cell engineering dedicated to advancing cell therapeutics, has announced the retirement of board member Art Mandell. His retirement will take effect on December 31, 2024. Mandell has been an integral part of MaxCyte's board since 2006, contributing significantly to the company’s journey, particularly during its public offerings on both the UK AIM exchange and the US Nasdaq, as well as the development of its innovative ExPERT™ platform.
Contributions to the Cell Engineering Sector
The leadership of Art Mandell at MaxCyte has proved invaluable for the growth and positioning of the company in the competitive field of cell engineering. The board's chairman, Richard Douglas, expressed deep appreciation for Mandell’s profound insights and notable contributions throughout his tenure. Mandell has articulated his pride in the evolution of MaxCyte and has expressed confidence in the company’s ongoing endeavors, particularly in offering groundbreaking solutions in the realm of cell and gene therapies.
Understanding the ExPERT™ Platform
MaxCyte’s ExPERT™ platform stands out in the market for its robust support across the lifecycle of cell therapy development, ranging from initial discovery to full commercialization. This powerful platform is equipped with a variety of instruments, proprietary disposables, and comprehensive software protocols. Furthermore, it is supported by an extensive intellectual property portfolio that adds to its strength and reliability.
Looking Ahead Post-Retirement
While the specifics regarding Mandell’s successor or potential shifts in the board's structure following his retirement remain under wraps, MaxCyte’s commitment to the advancement of cell-based medicines is unwavering. The company continues to forge ahead with strategic platform licenses and is actively involved in supporting the pioneering efforts of the industry’s first FDA-approved non-viral cell therapy, which utilizes CRISPR technology.
Frequently Asked Questions
Why did Art Mandell retire from MaxCyte's board?
Art Mandell retired to reflect on his lengthy tenure and to allow new leadership to guide MaxCyte's future.
What impact did Mandell have on MaxCyte?
Mandell played a significant role in MaxCyte’s growth, especially during its IPO and the development of the ExPERT™ platform.
What is the ExPERT™ platform?
The ExPERT™ platform is a comprehensive system designed to support cell therapy development from discovery through commercialization.
What are MaxCyte’s future goals?
MaxCyte aims to continue advancing cell-based medicines and supporting innovative therapies such as CRISPR edited therapies.
Who will succeed Art Mandell on the board?
As of now, MaxCyte has not disclosed information regarding Mandell's successor on the board of directors.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
